Chapter 14 – FDA’s Coronavirus Treatment Acceleration Program (CTAP)
Recognizing the need for rapid COVID-19 pandemic response, the FDA has created the Coronavirus Treatment Acceleration Program (CTAP) to move new treatments to patients as quickly as possible while still maintaining scientifically based standards for evaluating treatment safety and effectiveness. The purpose of the program is to rapidly connect researchers with new treatment ideas to FDA staff, enhancing interactions and accelerating review. The CTAP webpage gives a snapshot of the therapeutic programs in process and email addresses for researchers to reach out directly to the relevant FDA center. CTAP is aligned with the FNIH-led international partnership for COVID-19 research (read more at this previous post).
Reach out to me if you want to know more or discuss your medical product development challenges.
https://calendly.com/katrinarogers
Text Copyright © 2020 Katrina Rogers